<DOC>
	<DOC>NCT00838084</DOC>
	<brief_summary>This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2811376 single doses, how the body handles the drug, and the drug's effect on the body.</brief_summary>
	<brief_title>A Safety Study of LY2811376 Single Doses in Healthy Subjects</brief_title>
	<detailed_description>This is a Phase 1 study with 2 parts, both in healthy subjects. Part 1 is a subject- and investigator-blind, placebo-controlled, randomized, 3 period, crossover study. Part 1 will assess the safety and tolerability of LY2811376 single doses, how the body handles the drug, and the drug's effect on the body. Part 2 is a subject- and investigator-blind, placebo-controlled, randomized study to assess the safety and tolerability of a LY2811376 single dose, how the body handles the drug, and the drug's effect on the body including in cerebrospinal fluid.</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Healthy men and nonchildbearing potential women 20 years or older Body mass index between 1832kg/m2 Taking overthecounter or prescription medication with the exception of vitamins or minerals or stable doses of thyroid or estrogen hormone replacement. Smoke more than 10 cigarettes per day. Consume more than 5 cups of coffee per day.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>